IN2014DN01959A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN01959A IN2014DN01959A IN1959DEN2014A IN2014DN01959A IN 2014DN01959 A IN2014DN01959 A IN 2014DN01959A IN 1959DEN2014 A IN1959DEN2014 A IN 1959DEN2014A IN 2014DN01959 A IN2014DN01959 A IN 2014DN01959A
- Authority
- IN
- India
- Prior art keywords
- prostate cancer
- levels
- castration resistant
- reducing
- resistant prostate
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 abstract 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 11
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 4
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract 3
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract 3
- 229940040129 luteinizing hormone Drugs 0.000 abstract 3
- 230000001394 metastastic effect Effects 0.000 abstract 3
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229960003604 testosterone Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 abstract 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002638 palliative care Methods 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/215,679 US9427418B2 (en) | 2009-02-23 | 2011-08-23 | Estrogen receptor ligands and methods of use thereof |
| PCT/US2012/052141 WO2013043304A1 (en) | 2009-02-23 | 2012-08-23 | Estrogen receptor ligands and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01959A true IN2014DN01959A (enExample) | 2015-05-15 |
Family
ID=48444651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1959DEN2014 IN2014DN01959A (enExample) | 2011-08-23 | 2012-08-23 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2747562A4 (enExample) |
| JP (1) | JP2014524479A (enExample) |
| KR (1) | KR20140064906A (enExample) |
| CN (1) | CN103957706A (enExample) |
| AU (1) | AU2012312902B2 (enExample) |
| CA (1) | CA2845890A1 (enExample) |
| IL (1) | IL231070A0 (enExample) |
| IN (1) | IN2014DN01959A (enExample) |
| MX (1) | MX2014002105A (enExample) |
| RU (1) | RU2014111060A (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11679160B2 (en) * | 2017-09-27 | 2023-06-20 | Targimmune Therapeutics Ag | Castration resistant prostate cancer |
| PH12021551657A1 (en) * | 2019-01-30 | 2022-05-02 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020157334A1 (en) * | 2019-02-01 | 2020-08-06 | Fondazione Per L'istituto Oncologico Di Ricerca (Ior) | Methods of treating castrate-resistant prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| CA2631331C (en) * | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Nuclear receptor binding agents |
| CN102413692B (zh) * | 2009-02-23 | 2015-01-07 | Gtx公司 | 雌激素受体配体及其使用方法 |
-
2012
- 2012-08-23 RU RU2014111060/15A patent/RU2014111060A/ru not_active Application Discontinuation
- 2012-08-23 EP EP12834287.0A patent/EP2747562A4/en not_active Withdrawn
- 2012-08-23 CN CN201280051979.4A patent/CN103957706A/zh active Pending
- 2012-08-23 IN IN1959DEN2014 patent/IN2014DN01959A/en unknown
- 2012-08-23 JP JP2014527312A patent/JP2014524479A/ja active Pending
- 2012-08-23 MX MX2014002105A patent/MX2014002105A/es unknown
- 2012-08-23 CA CA2845890A patent/CA2845890A1/en not_active Abandoned
- 2012-08-23 KR KR1020147007549A patent/KR20140064906A/ko not_active Withdrawn
- 2012-08-23 AU AU2012312902A patent/AU2012312902B2/en not_active Ceased
-
2014
- 2014-02-20 IL IL231070A patent/IL231070A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140064906A (ko) | 2014-05-28 |
| JP2014524479A (ja) | 2014-09-22 |
| AU2012312902B2 (en) | 2016-03-17 |
| EP2747562A4 (en) | 2015-05-06 |
| CA2845890A1 (en) | 2013-03-28 |
| RU2014111060A (ru) | 2015-09-27 |
| IL231070A0 (en) | 2014-03-31 |
| AU2012312902A1 (en) | 2013-05-23 |
| EP2747562A1 (en) | 2014-07-02 |
| MX2014002105A (es) | 2014-09-25 |
| CN103957706A (zh) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008879A (es) | Ligandos de receptor de estrogeno y metodos de uso de los mismos. | |
| IN2015DN01046A (enExample) | ||
| MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
| PL2434891T3 (pl) | Sposoby leczenia nowotworu złośliwego i stanów nienowotworowych | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| SI2444085T1 (sl) | Diarilhidantoinske spojine kot antagonisti androgenega receptorja za zdravljenje raka | |
| MX2010003013A (es) | Inhibicion de angiogenesis. | |
| IL231107A (en) | An aryl-hydrocarbon receptor inhibitor (AHR) for the treatment and / or prevention of quinoranine-dependent cancer | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| MY193562A (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
| MX2013009732A (es) | Terapias de combinacion comprendiendo agentes anti-erbb3. | |
| WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
| WO2012078633A8 (en) | Methods of inhibiting metastasis from cancer | |
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX360774B (es) | Antagonistas de progesterona. | |
| PH12012500916B1 (en) | Treatments for gastrointestinal disorders | |
| WO2011011692A3 (en) | Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) | |
| PH12014502046A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
| PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| MX2013010530A (es) | Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. | |
| TN2012000205A1 (en) | Method and compositions for treating solid tumors and other malignancies | |
| JO3145B1 (ar) | مركبات مفيدة لتثبيط chk1 | |
| IN2014DN01959A (enExample) | ||
| WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists |